Infect Chemother.
2021 Jun;53(2):395-403. 10.3947/ic.2021.0304.
Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARSCoV-2 Monoclonal Antibody Treatment of Patients with COVID-19
- Kim SB
1 - Kim J2
- Huh K3
- Choi WS1
- Kim YJ4
- Joo EJ5
- Kim YJ6
- Yoon YK1
- Heo JY7
- Seo YB8
- Jeong SJ9
- Yu SY2
- Peck KR3
- Choi M2
- Yeom JS9
- Korean Society of Infectious Diseases (KSID)
- Affiliations
-
- 1Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
- 2Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare, Collaborating Agency, Seoul, Korea
- 3Division of Infectious Diseases, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 4Division of Infectious Diseases and Immunodeficiency, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 5Division of Infectious Diseases, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Korea
- 6Division of Infectious Diseases, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 7Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea
- 8Division of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea
- 9Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2517472
- DOI: http://doi.org/10.3947/ic.2021.0304
Abstract
- Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
- Evidence-based Healthcare in Korea
- Korean Clinical Imaging Guidelines for Justification of Diagnostic Imaging Study for COVID-19
- Burnout among Healthcare Workers during COVID-19 Pandemic
- Empirical Treatment and Prevention of COVID-19
